Connect Biopharma Holdings Limited
$2.20
+0.0310 (1.43%)
Join the Connect Biopharma Holdings Limited Investor Community
Get the latest news and company updates delivered straight to your inbox. Subscribe for free to stay ahead of the story and follow Connect Biopharma Holdings Limited as new developments unfold.
Analyst Report
Initiating Coverage with Outperform Rating, $7.50 Price Target
Company Overview
Connect Biopharma Holdings Ltd. is a clinical-stage biotechnology company advancing innovative therapeutics designed to transform the treatment landscape for inflammatory diseases driven by T-cell dysfunction. The company’s lead candidate, rademikibart, is a next-generation, highly differentiated monoclonal antibody targeting interleukin-4 receptor alpha (IL-4Rα), with potential applications in asthma and chronic obstructive pulmonary disease (COPD)—markets collectively representing multi-billion-dollar commercial opportunities. Backed by robust clinical data from a global Phase 2 study demonstrating superior efficacy, rapid onset of action, and a favorable safety profile, Connect is strategically positioned to enter clinical trials targeting acute exacerbations in respiratory diseases, an area of significant unmet medical need. With a newly strengthened U.S.-based management team experienced in successful drug development and regulatory execution, including having collectively received FDA marketing approval for 16 therapeutic products, and with deep expertise in business development, corporate strategy, finance and operations, Connect Biopharma is uniquely positioned for substantial growth as it moves toward pivotal clinical milestones and commercialization.
Value Proposition
Connect Biopharma presents a compelling investment opportunity in the biotechnology space, poised to redefine treatment paradigms for severe respiratory diseases with significant unmet medical needs.
The company’s lead asset, rademikibart, is an innovative next-generation monoclonal antibody targeting IL-4Rα, uniquely positioned to address both acute and chronic exacerbations in asthma and COPD—indications currently underserved by existing biologics. Backed by recently published Phase 2 clinical data in AJRCCM demonstrating rapid, superior efficacy and sustained lung function improvement, rademikibart holds potential best-in-class status, differentiating itself clearly from market leaders like dupilumab and benralizumab.
Independent market analyses project potential peak annual worldwide sales exceeding $3 billion in asthma and $2 billion in COPD, underscoring significant commercial upside.
Connect Biopharma’s strengthened U.S.-focused leadership, clear regulatory pathway to late-stage clinical development, and solid financial position—with sufficient cash runway through key clinical milestones into 2027—present investors with an attractive and timely opportunity to participate in the company’s promising growth trajectory.
Key Catalysts
- Obtained FDA alignment for acute asthma and COPD studies and for registration pathway
- Adopted U.S. filings with the SEC
- Initiated Phase 2 acute asthma and COPD studies in May 2025
- Complete Phase 2 acute exacerbation studies in 1H2026
Investor Presentation
Investment Highlights
Innovative Biologic Therapy Targeting High-Unmet-Need Respiratory Diseases
- Developing rademikibart, a differentiated, next-generation anti-IL-4Rα monoclonal antibody designed to treat acute exacerbations in asthma and COPD
- Clinically validated mechanism of action with potential best-in-class profile: rapid onset, sustained efficacy, and favorable safety compared to currently approved biologics
- Potential to address unmet needs in acute treatment settings where other biologics, such as dupilumab are expressly prohibited
Robust Clinical Data Supports Differentiation and Competitive Advantage
- Phase 2b global study results show significant and rapid improvement in lung function (FEV1) within one week, with most of the benefit present in one day and sustained effects observed over 24 weeks
- Best-in-class lung function improvement compared to current biologics, particularly in high-eosinophil patient populations
- Favorable safety profile, with substantially lower rates of hyper-eosinophilia compared to primary competitor dupilumab.
Significant Commercial Opportunity in Large Asthma and COPD Markets
- Annual U.S. market includes ~1 million asthma and ~1.3 million COPD patients experiencing severe exacerbations requiring urgent treatment at an emergency room
- Acute indication differentiates rademikibart from other biologics, creating a clear market-entry advantage and an important driver for chronic use
- Independent market research projects potential peak worldwide sales of greater than $3 billion in asthma and greater than $2 billion in COPD
Clear Regulatory Pathway for Chronic Disease and Near-Term Catalysts in Acute Disease
- FDA alignment secured for moving rademikibart into Phase 3 trials for chronic asthma indications based on strong Phase 2 results
- Initiated Phase 2 Seabreeze STAT studies in May 2025 evaluating rademikibart as an adjunct treatment for acute exacerbations in asthma and COPD; topline data expected in 1H 2026
- Simcere Pharmaceutical, the company’s exclusive licensee in China, submitted an NDA to Chineses regulator for rademikibart for the treatment of atopic dermatitis; CNTB eligible to receive up to $110M in milestone payments plus double-digit royalties
Experienced Management Team and Strong Financial Position
- New U.S.-centric leadership team assembled in 2024, with a track record of successful clinical and regulatory execution
- Cash runway into 2027, fully funding planned acute asthma and COPD studies
- Focused corporate strategy optimizing capital allocation towards high-potential U.S. market opportunities with minimized exposure in non-core geographic regions
Pipeline
Clinical Trial Pipeline Stages
| Drug Name | Stage |
|---|---|
| Rademikibart (CBP-201) (Th2 cell modulator)DetailsAtopic dermatitis | Phase 3 |
| Rademikibart /CBP-201 (Th2 cell modulator)DetailsAsthma | Phase 2b |
| Icanbelimod (CBP-307) (Small molecule targeting S1P1) (Th1 cell modulator)DetailsUlcerative colitis | Phase 2 |
| CBP-174 (Peripherally restricted H3 receptor antagonist)DetailsChronic pruritus | Phase 1 |
| Icanbelimod (CBP-307) (Small molecule targeting S1P1) (Th1 cell modulator)DetailsCrohns disease | Failed |
| Rademikibart (CBP-201) (Th2 cell modulator)DetailsChronic rhinosinusitis, Chronic rhinosinusitis with nasal polyps | Failed |
Sign Up For CNTB Email News Alerts
Disclosure
RedChip Companies, Inc. research reports, company profiles, and other investor relations materials, publications or presentations, including web content, are based on data obtained from sources we believe to be reliable but are not guaranteed as to accuracy and are not purported to be complete. As such, the information should not be construed as advice designed to meet the particular investment needs of any investor. Any opinions expressed in RedChip reports, company profiles, or other investor relations materials and presentations are subject to change. RedChip Companies and its affiliates may buy and sell shares of securities or options of the issuers mentioned on this website at any time.
RedChip Visibility is a division of RedChip Companies, Inc. and offers research services to paying clients. In the purview of Section 17(b) of the Securities Act of 1933 and in the interest of full disclosure, we call the reader's attention to the fact that RedChip Companies Inc. is an investor relations firm hired by certain companies to increase investor awareness to the small-cap equity community.
Stock market investing is inherently risky. RedChip Companies is not responsible for any gains or losses that result from the opinions expressed on this website, in its research reports, company profiles, or in other investor relations materials or presentations that it publishes electronically or in print.
We strongly encourage all investors to conduct their own research before making any investment decision. For more information on stock market investing, visit the Securities and Exchange Commission ("SEC") at www.sec.gov and/or the Ontario Securities Commission (“OSC”) at www.osc.gov.on.ca.
Connect BioPharma (CNTB) is a client of RedChip Companies. CNTB agreed to pay RedChip Companies, Inc. a $12,500 monthly cash fee, beginning in March 2025, for six month of investor awareness services. CNTB also agreed to pay RedChip a $50,000 fee for a 10-day national TV ad campaign aired weekdays from March 17 through March 28, 2025, a $75,000 fee for a 10-day national TV ad campaign aired weekdays from May 5 through May 16, 2025, and a $75,000 fee for a 10-day national TV ad campaign aired weekdays from July 14 through July 25, 2025.
Investor awareness services and programs are designed to help small-cap companies communicate their investment characteristics. RedChip investor awareness services include the preparation of a research profile(s), multimedia marketing, and other awareness services.